Use access key #2 to skip to page content.

MightyMaven's rating is .

  • Score: N/A
  • Accuracy: N/A

A player's rating indicates his percentile rank in CAPS. MightyMaven is outperforming % of all CAPS players. A player's score is the total percentage return of all his picks subtracting out the S&P. A player's accuracy is how often that player has made correct predictions.

To calculate a player's rating, we take 2/3 of his score percentile and 1/3 of his accuracy percentile. For further information, read the Player Ratings section of the Help page.

Average Pick Score is a player's total score divided by the total number of picks (active and closed). It represents the player's average return after subtracting out the market's performance.

Average Pick Rating is the average stock rating of a player's total picks. Underperform picks are flip-flopped, so a underperform call on a one-star stock is treated like an outperform call on a five-star stock. This rating reflects how closely your picks are aligned with CAPS ratings.

What's the deal with N/A?
You need to have at least seven active stocks in order to see your calculated accuracy and total score.

MightyMaven (< 20)

No Lucky Charms earned yet.

MightyMaven beat the market on Friday

Player Rating CAPS Rating


Rank: N/A
Score: N/A
Accuracy: N/A
Average Pick Score:
Average Pick Rating:
All-Time Best: XXII +52.01
All-Time Worst: GSB -66.09

Score Comparison vs. MightyMaven

Player History

How are these stats calculated?

MightyMaven's Latest Blog Post



Aphria's Cannabis Going Into Phase III Trials

September 18, 2017 – Comments (1) | RELATED TICKERS: APHQF

Aphria Distinguished by its Stake in Tetra BP:Aphria has worked to distinguish itself from just any marijuana grower out there. They have done so in a number of ways, but the best by far is their partnership with fellow Canadian company, Tetra Bio Pharma, to bring smokeable dried cannabis through the prescription drug clinical trials process, from Phase I through Phase III, and obtain a DIN drug ID number from Health Canada and the US FDA. Yes, it is really happening.  [more]

MightyMaven's Stock Picks

Results 1 - 2 of 2  

picks per page. CHANGE Expand All Pitches

TickerCAPS RatingCallTime FrameStart PriceToday (Change)Stock
07/14/17 GSB Outperform 5Y $5.29 $3.89
( +2.64%)
-26.46%+1.56%-28.02 Toggle the visibility of 60-Second Pitch and replies
07/06/17 XXII Outperform 5Y $1.69 $2.62
( -9.03%)
+55.12%+3.11%+52.01 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 2 of 2  

Featured Broker Partners